In DLBCL, aberrant activation of the NF-κB is thought to be closely related to tumor cells, patient survival, and drug resistance, and inhibiting the NF-κB activity significantly enhances chemotherapeutic drug-induced apoptosis [9]. This evidence concerns the gene NFKB1 and neoplasm.